Publications by authors named "Itaru Hisauchi"
Aim: We aimed to determine whether baseline high-density lipoprotein (HDL) cholesterol efflux capacity (CEC) at the time of coronary angiography (CAG) could serve as a prognostic marker for future major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) through a systematic review and meta-analysis.
Methods: The MEDLINE, Cochrane, and Embase databases were used for data collection. As of April 2024, 2,871 studies have been identified.
Article Synopsis
- A trial, STOPDAPT-3, was conducted to compare aspirin monotherapy and clopidogrel monotherapy after short-term dual antiplatelet therapy in patients who underwent percutaneous coronary intervention using drug-eluting stents.
- The study involved 5,833 patients who were followed for 30 days, focusing on cardiovascular events (like heart attacks) and bleeding complications as primary endpoints.
- Results showed that aspirin and clopidogrel monotherapy had similar rates of cardiovascular and bleeding events up to one year after the intervention, indicating both treatments are equally effective in these contexts.
Article Synopsis
- The study aimed to assess the effects of starting sacubitril/valsartan (Sac/Val) therapy during hospitalization for acute heart failure (AHF) on NT-proBNP levels in Japanese patients.
- It involved a randomized trial with 400 patients, comparing those who switched to Sac/Val versus those who continued standard therapy, measuring changes in NT-proBNP at 4 and 8 weeks.
- Results showed that the Sac/Val group experienced significantly greater reductions in NT-proBNP levels, particularly in patients with lower left ventricular ejection fractions, with no significant safety concerns noted.
Article Synopsis
- Current guidelines suggest avoiding anticoagulation after PCI for acute coronary syndrome (ACS), but this recommendation lacks strong evidence.
- In a study analyzing outcomes of patients with ACS who did or did not receive post-PCI heparin, those receiving heparin had a significantly higher risk of bleeding and a slightly increased risk of cardiovascular events.
- The use of post-PCI heparin in ACS patients was common, but it was linked to increased bleeding without demonstrating any clear benefit in reducing serious cardiovascular outcomes.
Article Synopsis
- - The systematic review and meta-analysis assessed the effectiveness of paclitaxel-coated balloon angioplasty (PCB) for treating new lesions in patients with acute coronary syndrome (ACS) versus drug-eluting stents (DES).
- - They analyzed nine studies involving over 2,000 cases, finding that the major adverse cardiac event (MACE) rates were similar between PCB (8.42%) and DES (10.62%) groups, with no significant differences in several health outcomes.
- - The results suggest that PCB angioplasty is a feasible alternative to DES for managing de novo lesions in ACS patients during emergency procedures, with comparable midterm outcomes.
Background: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials.
Methods: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.
Article Synopsis
- Dotinurad is a new medication that helps lower uric acid levels by promoting its excretion in patients suffering from hyperuricemia and hypertension.
- This study involved a 24-week trial where 50 patients received varying doses of dotinurad, measuring changes in serum uric acid levels and cardiovascular health indicators.
- Results showed a significant reduction in uric acid levels by 35.8%, with improvements noted in arterial stiffness and oxidative stress markers, indicating potential additional heart and vascular benefits from the treatment.
The prognostic impact of CHADS, CHADS-VASc, and CHADS-VASc-HS scores on clinical outcomes after drug-eluting stent (DES) placement has not been fully elucidated. The present study was a retrospective, non-randomized, single-center, and lesion-based study. Target lesion failure (TLF), comprising cardiac death, non-fatal myocardial infarction, and target vessel revascularization, occurred in 7.
View Article and Find Full Text PDFArticle Synopsis
- A retrospective study was conducted to compare the effectiveness of paclitaxel-coated balloon (PCB) angioplasty versus drug-eluting stents (DESs) for treating new blockages in large coronary vessels.
- Out of 154 patients treated, the incidence of target lesion failure (TLF) was similar between the PCB group (6.8%) and the DES group (14.6%), indicating that PCB is as effective as DESs in preventing serious cardiac events.
- Angiographic results showed no significant cases of restenosis (re-narrowing) following PCB treatment, suggesting it may be a promising option for coronary interventions without negative outcomes.
Article Synopsis
- The study investigates the safety and effectiveness of drug-coated balloon (DCB) angioplasty compared to drug-eluting stents (DESs) for treating coronary stenosis, involving 588 patients treated between 2016 and 2019.
- Overall target lesion failure (TLF) rates were similar between the DCB group (9.6%) and DES group (10.2%), indicating comparable clinical safety.
- Additionally, the angiographic restenosis rates were not significantly different: DCB at 6.3% and DES at 10.1%, with late lumen enlargement identified as a predictor for better outcomes in DCB treatments.
Article Synopsis
- Preventing phrenic nerve injury (PNI) during balloon-based ablation is crucial, as the phrenic nerve is located near the SVC-RA junction where the ablation takes place.
- A study compared cryoballoon ablation (CBA) and hot-balloon ablation (HBA) in patients with atrial fibrillation, revealing that CBA led to a higher incidence of transient PNI (7.3% vs 1.1%) but all cases were temporary.
- CBA created larger and more frequent lesions at the SVC-RA junction compared to HBA, suggesting that the design and positioning of the balloon systems play a significant role in the extent of damage to surrounding structures
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce the risk of heart failure progression and mortality rates. Moreover, osmotic diuresis induced by SGLT2 inhibition may result in an improved heart failure prognosis. Independent of conventional diuretics in patients with type 2 diabetes (T2D) and chronic heart failure, especially in patients with heart failure with preserved ejection fraction (HFpEF), it is unclear whether SGLT2i chronically reduces estimated plasma volume (ePV).
View Article and Find Full Text PDFArticle Synopsis
- The study explored whether fully circumferential lesions are necessary for achieving pulmonary vein isolation (PVI) during laser balloon ablation, especially considering potential complications like stenosis.
- In a trial with 51 patients, researchers found that 39% of PVs achieved early PVIs with significantly better success in lower PVs compared to upper PVs (60.1% vs. 17.6%).
- The results suggest that additional research is needed to understand the energy requirements for lower PVs to prevent chronic narrowing, as energy delivery was less for lower PVs yet stenosis rates were similar for both upper and lower PVs after 6 months.
We conducted a single-center, retrospective, lesion-based study to examine the safety and efficacy of drug-coated balloons (DCBs) for de novo coronary stenosis in patients with acute coronary syndrome (ACS) by comparing them with those of drug-eluting stents (DESs).A total of 309 consecutive lesions in patients with ACS who were successfully treated by emergent procedures using either a DCB (n = 107) or a DES between January 2016 and December 2019 were included in the study. The primary endpoint was the incidence of target lesion failure (TLF), defined as cardiac death without mortality due to ACS, non-fatal myocardial infarction, and any target lesion revascularization, including acute occlusion, after DCB use and definite stent thrombosis after DES placement.
View Article and Find Full Text PDFAim: We examined the impact of baseline high-density lipoprotein cholesterol efflux capacity (CEC) on major cardiac adverse events (MACE) in patients with coronary artery disease (CAD) during a long-term secondary prevention.
Method: CEC was measured using a cell-based efflux system in (3)[H]-cholesterol-labeled J774 macrophages in apolipoprotein B-depleted plasma between January 2011 and January 2013. Patients with CAD were divided into 2 groups as a boundary CEC value of 1: 0.
Aims/introduction: Recent clinical trials on sodium-glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear.
Materials And Methods: The effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized (EMBLEM) trial in patients with type 2 diabetes and cardiovascular disease showed empagliflozin treatment for 24 weeks had no effect on peripheral endothelial function measured by reactive hyperemia peripheral arterial tonometry.
Aims: Little is known about the impact of sodium glucose co-transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes in N-terminal pro-brain natriuretic peptide (NT-proBNP), in that patient population.
Methods And Results: Patients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting-dose: 0.
Here, we report on a healthy 30-year-old man with no significant medical history, who tested negative for human immunodeficiency virus antigenemia but developed Aspergillus pancarditis. A case of this kind is extremely rare, and to the best of our knowledge, this is the first report of a patient with Aspergillus pancarditis, which generally leads to a very poor outcome, who had a long-term favorable clinical course. A biopsy from the right atrium of hypertrophied atrial septum was essential for obtaining the definitive diagnosis.
View Article and Find Full Text PDFBackground: Percutaneous coronary intervention (PCI) is an effective treatment for patients with ischemic heart disease. In particular, restenosis is suppressed after drug-eluting stent (DES) implantation. However, several problems remain.
View Article and Find Full Text PDFHyperuricemia is a known cardiovascular risk factor. The angiotensin II receptor blocker (ARB) losartan is known to decrease serum uric acid (UA) level. A recent in vitro study demonstrated a strong interaction between irbesartan and UA transporters that exceeded that of losartan.
View Article and Find Full Text PDF